NCT04803305: Study to Compare the Effects of Repeated Doses of an Investigational New Drug (PF-06946860) and a Placebo on Appetite in Participants With Advanced Cancer and Anorexia

Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Active, not recruiting
Phase 1
Drug Category: Therapeutic Antibody

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients with known symptomatic brain metastases requiring steroids

Comments are closed.

Up ↑